LACTAM RING-CONTAINING CEREBRAL CIRCULATION METABOLISM IMPROVER

• Main Authors: KUBO YOSHIKO, FUJIMOTO KOICHI, IWATA NOBUYOSHI, SHIMOJI YASUO, KANEZAKI TAKUO, YANAGISAWA HIROAKI
• Format: Patent
• Language: English
• Published: 21.04.1992
• Subjects: CHEMISTRY; CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION ORPROCESSING OF GOODS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS; TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINSTCLIMATE CHANGE

PURPOSE:To obtain an excellent cerebral circulation metabolism improver strengthening anti-reserpine action and blood viscosity improving action, comprising a 2-morphoplinylmethyl group-lactam as an active ingredient. CONSTITUTION:An excellent cerebral circulation metabolism improver comprising a compound shown by formula I (R and R are H, alkyl, alkoxy, halogen, or bonded to form alkylene or alkylenedioxy; R is H or alkyl; X is CH2, O or S) or a pharmaceutically acceptable salt thereof such as 3,4-dihydro-1-[(2- morphoplinyl)methyl]-2(1H)-quinolone maleate as an active ingredient. The compound shown by formula I is obtained by reacting a lactam compound shown by formula II with a morpholine derivative shown by formula III (Y is halogen or sulfonyloxy; R is amino-protecting group) and then protecting or reacting the compound shown by formula II with a compound shown by formula TV (R is alkyl).